# Expanded Access Program for Melphalan Flufenamide (Melflufen) in Triple Class Refractory Multiple Myeloma

> **NCT04534322** · — · APPROVED_FOR_MARKETING · sponsor: **Oncopeptides AB**

## Conditions studied

- Relapsed and/or Refractory Multiple Myeloma

## Interventions

- **DRUG:** Melphalan Flufenamide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT04534322
- **Lead sponsor:** Oncopeptides AB
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2021-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04534322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04534322, "Expanded Access Program for Melphalan Flufenamide (Melflufen) in Triple Class Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04534322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*